Cingulate Inc. (CING)
CING Stock Price Chart
Explore Cingulate Inc. interactive price chart. Choose custom timeframes to analyze CING price movements and trends.
CING Company Profile
Discover essential business fundamentals and corporate details for Cingulate Inc. (CING) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2021
Employees
13.00
Website
https://www.cingulate.comCEO
Shane J. Schaffer
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Financial Timeline
Browse a chronological timeline of Cingulate Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.82.
Earnings released on 19 Aug 2025
EPS came in at -$1.09 falling short of the estimated -$0.82 by -32.93%.
Earnings released on 8 May 2025
EPS came in at -$1.04 falling short of the estimated -$1.00 by -4.00%.
Earnings released on 27 Mar 2025
EPS came in at -$0.14 surpassing the estimated -$1.48 by +90.54%.
Earnings released on 7 Nov 2024
EPS came in at -$1.83 surpassing the estimated -$2.22 by +17.57%.
Earnings released on 13 Aug 2024
EPS came in at -$5.47 surpassing the estimated -$5.64 by +3.01%.
Stock split effective on 9 Aug 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2024
EPS came in at -$7.20 surpassing the estimated -$26.41 by +72.74%.
Earnings released on 29 Mar 2024
EPS came in at -$7.66 falling short of the estimated -$4.86 by -57.61%, while revenue for the quarter reached -$3.85B .
Stock split effective on 30 Nov 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$72.03 falling short of the estimated -$57.62 by -25.01%.
Earnings released on 14 Aug 2023
EPS came in at -$136.85 falling short of the estimated -$0.35 by -39.00K%.
Earnings released on 10 May 2023
EPS came in at -$84.03 falling short of the estimated -$64.83 by -29.62%.
Earnings released on 10 Mar 2023
EPS came in at -$98.44 falling short of the estimated -$86.43 by -13.90%.
Earnings released on 14 Nov 2022
EPS came in at -$86.43 falling short of the estimated -$0.37 by -23.26K%.
Earnings released on 11 Aug 2022
EPS came in at -$86.43 falling short of the estimated -$0.58 by -14.80K%.
Earnings released on 12 May 2022
EPS came in at -$105.64 falling short of the estimated -$0.23 by -45.83K%.
Earnings released on 10 Mar 2022
EPS came in at -$0.32 surpassing the estimated -$0.39 by +17.95%.
Earnings released on 9 Dec 2021
EPS came in at -$30.40 .
Earnings released on 30 Sept 2021
EPS came in at -$324.48 .
Earnings released on 31 Mar 2021
EPS came in at -$28.31 .
Earnings released on 31 Dec 2020
EPS came in at -$25.33 .
Earnings released on 30 Sept 2020
EPS came in at -$24.21 .
CING Stock Performance
Access detailed CING performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.